Autonomix Medical, Inc.
Financial highlights
| Metric | FY 03/31/26 | FY 03/31/25 | FY 03/31/24 | FY 03/31/23 | FY 03/31/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $0 | $0 | $0 | — |
| Research and development | $7.1M | $4.7M | $2.2M | $745,000 | — |
| Operating expenses | $17.0M | $11.6M | $12.0M | $2.0M | — |
| Operating income | -$17.0M | -$11.6M | -$12.0M | -$2.0M | — |
| Interest expense | $0 | $176,000 | $79,000 | $0 | — |
| Pretax income | -$16.7M | -$11.4M | -$15.4M | -$2.0M | — |
| Income tax expense | $0 | $0 | $0 | $0 | — |
| Net income | -$16.7M | -$11.4M | -$15.4M | -$2.0M | — |
| Balance Sheet | |||||
| Cash and equivalents | $7.0M | $9.1M | $8.6M | $865,000 | — |
| Current assets | $7.6M | $9.6M | $9.4M | $865,000 | — |
| Total assets | $7.6M | $9.8M | $9.4M | $865,000 | — |
| Current liabilities | $1.7M | $1.7M | $777,000 | $221,000 | — |
| Total liabilities | $1.7M | $1.7M | $1.8M | $221,000 | — |
| Stockholders' equity | $5.9M | $8.1M | $7.6M | $644,000 | $2.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$12.3M | -$8.3M | -$6.6M | -$1.9M | — |
| Depreciation and amortization | $12,000 | $183,000 | $81,000 | $0 | — |
| Stock-based compensation | $529,000 | $1.6M | $618,000 | $0 | — |
| Capital expenditure | $10,000 | $14,000 | $19,000 | $0 | — |
| Free cash flow | -$12.3M | -$8.3M | -$6.6M | -$1.9M | — |
Shares outstanding 11.4M · Free float 47.9%
Annual filing data through FY ended March 31, 2026; float as of July 14, 2026.